HC Wainwright Reaffirms “Buy” Rating for Alpha Tau Medical (NASDAQ:DRTS)

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a report issued on Friday,Benzinga reports. The firm currently has a $9.00 price objective on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $7.00 price objective on shares of Alpha Tau Medical in a research report on Thursday, August 15th.

Alpha Tau Medical Trading Up 9.0 %

Shares of NASDAQ:DRTS opened at $2.53 on Friday. The stock has a market cap of $176.23 million, a PE ratio of -5.88 and a beta of 0.77. The company has a quick ratio of 11.60, a current ratio of 10.99 and a debt-to-equity ratio of 0.08. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $3.40. The business has a 50 day moving average of $2.29 and a 200-day moving average of $2.30.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors have recently made changes to their positions in the stock. Aptus Capital Advisors LLC grew its stake in Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. increased its stake in Alpha Tau Medical by 83.7% in the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares during the last quarter. Caprock Group LLC bought a new position in Alpha Tau Medical in the second quarter valued at approximately $59,000. Finally, Levin Capital Strategies L.P. raised its position in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock valued at $999,000 after purchasing an additional 8,641 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.